ArticlePloS one2025
The role and mechanism of irisin/NLRP3 signal in aerobic exercise ameliorating blood glucose homeostasis in pre-diabetic mice.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myokine Signaling in Sarcopenia-Associated Chronic Musculoskeletal Pain: A Systematic Review of Inflammatory Mechanisms.International journal of molecular sciences · 2026Pooled it
- Exercise-Induced Exerkines: Multi-Nodal Suppression of the NLRP3 Inflammasome and Translational Potential.Medicinal research reviews · 2026Review
- The Role of Skeletal Muscle Mitochondria in NLRP3 Inflammasome Signaling.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-diabetic mellitus (PDM) is characterized by chronic low-grade inflammation, primarily driven by NLRP3 inflammasome hyperactivation and a concurrent deficiency of the myokine irisin. MCC950 is a highly specific inhibitor of the NLRP3 inflammasome, and aerobic exercise has also been shown to effectively suppress its activation. However, the underlying molecular mechanisms remain unclear. The aim of this project was to explore whether the irisin/NLRP3 signaling pathway was regulated by aerobic exercise in mice with PDM. Forty mice were divided into: the common diet group (DC group, N = 10), and the high-fat diet group (HFD group, N = 30). The HFD group received a high-fat diet combined with a single low-dose streptozotocin (STZ) injection to induce a pre-diabetic state. Successfully modeled mice were identified as PDM mice and randomly assigned into three subgroups: the PDM control group (PDM-DC group, N = 8), the PDM plus exercise group (PDM-EX group, N = 8), and the PDM plus MCC950 group (PDM-MC group, N = 8). The PDM-EX group performed treadmill exercise for 4 weeks (5 days/week, 12 m/min, 60 min/d). The PDM-MC group received NLRP3 inhibitor injections (MCC950, 10 mg/kg, 5 d/week) for 4 weeks. These results found that aerobic exercise and MCC950 ameliorated glycolipid metabolism, reduced insulin levels, and effectively facilitated the skeletal muscle remodeling in PDM mice. Compared with the DC group, PDM mice exhibited significantly downregulated FNDC5/irisin expression and upregulated NLRP3 and IL-18 expression (P < 0.05 or P < 0.01). Notably, aerobic exercise significantly increased FNDC5/irisin expression (P < 0.05), and decreased NLRP3 and IL-18 levels (P < 0.01). Cell experiments revealed that the mRNA and protein expression of NLRP3, IL-1β and IL-18 in the high glucose (HG) condition were higher compared with the lower glucose (CON) condition (P < 0.01). Treatment with irisin significantly attenuated these increases (P < 0.05 or P < 0.01). These findings demonstrate that aerobic exercise alleviates inflammation and ameliorates glycolipid metabolism in PDM mice by modulating the irisin/NLRP3 signaling pathway. Moreover, irisin effectively suppresses high glucose-induced upregulation of NLRP3, IL-1β, and IL-18, suggesting its potential therapeutic role in managing pre-diabetic inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.